ArticleOncology letters2025
Chronic myeloid leukemia with the e13a3 atypical fusion gene: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Two novel e13a3 variants detected in CML patients and their DNA breakpoint analysis.Frontiers in oncology · 2026Article
- The silent players: AtypicalOncology reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present report aims to improve our systematic understanding of the clinicopathological characteristics of chronic myeloid leukemia (CML) associated with the e13a3 transcript and to offer insights into potential treatment options for this rare subtype of CML. This case presents a 39-year-old male patient of Chinese descent diagnosed with CML featuring an atypical fusion gene identified by the e13a3 transcript. The patient was treated with second-generation tyrosine kinase inhibitor. An analysis of BCR-ABL1 using reverse transcription PCR following 6 months of treatment revealed a negative BCR-ABL1 fusion, indicating deep molecular remission. After 2 years of treatment, the patient developed skin sclerosis. Overall, to prevent missed diagnoses and misdiagnoses, it is recommended that a comprehensive clinical evaluation be performed, and the underlying etiology be proactively identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.